(secondQuint)Efficacy and Safety of Asacol 4.

8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis.

 The 800 mg Asacol cent tablets from Tillotts Pharma AG are being marketed in over 30 countries, mainly in Europe and Asia.

 Approved dosages for the treatment of active UC are between 2.

4 and 4.

8 g/day in analogy to the approved 400 mg dosage form.

 The present trial is planned to generate efficacy data to support the safe use of a 4.

8 g/day dose of the 800 mg dosage form in a well defined population of patients with mildly to moderately active UC.

 In keeping with the EMEA UC guideline the study will have a placebo-controlled 6 weeks induction treatment.

 After 6 weeks, treatment success will be evaluated using the modified UC disease activity index as primary efficacy measurement.

.

 Efficacy and Safety of Asacol 4.

8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis@highlight

The primary objective of the study is to determine the efficacy of Asacol cent 4.

8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).

